Levetiracetam Adjunct to Quetiapine for the Acute Manic Phase of Bipolar Disorder: A Randomized, Double-Blind and Placebo-Controlled Clinical Trial of Efficacy, Safety and Tolerability Publisher Pubmed



Zarezadeh F¹ ; Arbabi M^{1, 2, 3} ; Shamabadi A^{1, 4} ; Naderi S¹ ; Hasanzadeh A¹ ; Ostadpour M⁵ ; Samsami FS¹ ; Akhondzadeh S¹ Show Affiliations
Source: International Clinical Psychopharmacology Published:2022

Abstract

Unsatisfactory responses to bipolar disorder treatments have necessitated novel therapeutic approaches. Evidence of levetiracetam's effectiveness in mania was reported in previous studies. This study evaluated its efficacy, safety and tolerability as an adjunct to quetiapine in mania. Forty-four patients with Young Mania Rating Scale (YMRS) score ≥20 entered and were randomized to receive levetiracetam plus quetiapine or placebo plus quetiapine for 6weeks. Patients were assessed using the YMRS and Beck Scale for Suicidal Ideations (BSSI) at baseline and weeks 2, 4 and 6. Changes in the scores, remission rates and response to treatment were compared between the groups. Forty patients completed the trial. The general linear model (GLM) repeated measures demonstrated a significant effect for time×treatment interaction on the YMRS score during the trial (P=0.04). A greater reduction in YMRS scores was seen in the levetiracetam group compared with the placebo group from baseline to week 4 (P=0.045). Response to treatment was significantly better in the levetiracetam group (P=0.046). No significant effect for time×treatment interaction on BSSI score was seen in GLM repeated measures. Finally, there was no significant difference in the frequency of adverse events. Adjunctive levetiracetam is effective, safe and well-tolerated in patients with mania. Further high-quality, large-scale trials are recommended. Int Clin Psychopharmacol 37: 46-53 Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. © 2022 Lippincott Williams and Wilkins. All rights reserved.